Acute Myeloid Leukemia trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Acute Myeloid Leukemia. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month9 studies across 7 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT06001788Rate of dose limiting toxicities (DLTs) per dose level | Phase 1 | Recruiting | Aug 2026 | ≤ 11 d | 2026-04-14 |
November 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaNCT05587049observationalOverall Survival (OS) | — | Recruiting | Nov 2026 | ≤ 102 d | 2025-08-08 |
| ABBV | AbbVie | A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in ItalyNCT06058741observationalOverall Survival (OS) | — | Active, not recruiting | Nov 2026 | ≤ 102 d | 2025-04-22 |
| APTOF | Aptose Biosciences Inc. | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT03850574Frequency and severity of drug-related adverse events | Phase 1/2 | Recruiting | Nov 2026 | ≤ 102 d | 2025-08-26 |
| MGNX | MacroGenics | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesNCT05362773Number of severe side effects in patients receiving MGD024 | Phase 1 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-07-28 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in GreeceNCT05317494observationalPercentage of Participants Achieving Overall Survival (OS) | — | Recruiting | Dec 2026 | ≤ 133 d | 2025-07-16 |
| CERO | CERo Therapeutics Holdings, Inc. | CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)NCT06834282Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Part 1) | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2026-03-27 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics Inc. | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)NCT05143996Number of treatment emergent events (TEAEs) | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-01-16 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT06419634Incidence of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | 2027-02-01 | in 165 d | 2026-04-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Acute Myeloid Leukemia
most recently updated first247 studies match. Showing the first 100 of 247 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | $545.6B | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNCT07770698Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1/2 | Not yet recruiting | Drug: sonrotoclax, Azacitidine, Inotuzumab ozogamicin, Dexamethasone | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL, Relapsed, Pediatric ALL, Pediatric ALL, B Cell, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric AML, R/R AML, R/R B-cell ALL | 30 | Oct 2026 | 2030-04-30 | in 1,349 d | 2026-08-18 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in IndiaNCT07044687Percentage of Participants with Treatment Emergent Adverse Events (TEAE)s | Phase 4 | Recruiting | Drug: Venetoclax, Azacitidine, Azacitidine | Acute Myeloid Leukemia | 100 | 2025-07-24 | Nov 2027 | ≤ 467 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)NCT07306832Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation | Phase 1 | Recruiting | Drug: Pivekimab Sunirine | Acute Myeloid Leukemia | 18 | 2026-05-20 | Apr 2028 | ≤ 619 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)NCT07581002Phase 2: Complete remission (CR) | Phase 2/3 | Recruiting | Drug: Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK | Acute Myeloid Leukemia | 660 | 2026-06-30 | May 2032 | ≤ 2,111 d | 2026-08-14 |
| RIGL | Rigel Pharmaceuticals | $815M | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesNCT07486713Area Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs | Phase 4 | Recruiting | Drug: Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies | 16 | 2026-02-23 | 2027-04-30 | in 253 d | 2026-08-11 |
| MBRX | Moleculin Biotech, Inc. | $12M | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLNCT06788756Part A -Determination of Optimal Dosage Regimen | Phase 2/3 | Recruiting | Drug: Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Acute Myeloid Leukaemia (AML) | 312 | 2025-03-12 | Aug 2029 | ≤ 1,107 d | 2026-08-05 |
| MGNX | MacroGenics | $261M | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesNCT05362773Number of severe side effects in patients receiving MGD024 | Phase 1 | Active, not recruiting | Drug: MGD024 | Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia | 130 | 2022-07-13 | Nov 2026 | ≤ 102 d | 2026-07-28 |
| KURA | Kura Oncology, Inc. | $1.1B | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLNCT07007312Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS) | Phase 3 | Recruiting | Drug: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C) | Acute Myeloid Leukemia (AML) | 1,300 | 2025-09-26 | Nov 2031 | ≤ 1,928 d | 2026-07-27 |
| PFE | Pfizer | $155.3B | A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid LeukemiaNCT05189639observationalNumber of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | — | Recruiting | — | Acute Myeloid Leukemia | 165 | 2023-12-05 | 2027-08-30 | in 375 d | 2026-07-24 |
| SNDX | Syndax Pharmaceuticals | $1.8B | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationNCT07211958Event Free Survival | Phase 3 | Recruiting | Drug: Revumenib, Placebo, Intensive Chemotherapy Regimen | Acute Myeloid Leukemias | 468 | 2025-11-25 | Jun 2029 | ≤ 1,045 d | 2026-07-23 |
| CGEM | Cullinan Therapeutics Inc. | $1.3B | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsNCT07722767Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclax | Phase 1 | Not yet recruiting | Drug: CLN-049, Azacitidine, Venetoclax | AML (Acute Myeloid Leukemia) | 90 | 2026-10-15 | 2027-09-30 | in 406 d | 2026-07-23 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesNCT04227847Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: SEA-CD70, azacitidine, Venetoclax | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 178 | 2020-08-07 | 2027-07-04 | in 318 d | 2026-07-22 |
| LLY | Eli Lilly and Company | $1.15T | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsNCT04603001To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) | Phase 1 | Active, not recruiting | Drug: LY3410738, Venetoclax, Azacitidine | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs) | 260 | 2020-11-19 | 2023-07-03actual | — | 2026-07-22 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell TransplantationNCT07702578Relapse-free survival (RFS) | Phase 3 | Recruiting | Drug: TSC-101 · Other: Control | AML, MDS | 310 | 2026-06-18 | Jun 2029 | ≤ 1,045 d | 2026-07-22 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell TransplantationNCT05473910Occurrence of dose limiting toxicities | Phase 1 | Recruiting | Drug: SOC + TSC-101, SOC + TSC-100 · Other: Control | AML, MDS | 310 | 2022-11-01 | 2026-06-01actual | — | 2026-07-21 |
| TEM | Tempus AI | $8.6B | A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesNCT07154823observationalTo assess biomarker landscape in the progression as well as baseline biospecimen samples and correlate with with real-world outcomes across multiple hematologic indications. | — | Recruiting | Other: None - Observational Study | Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL) | 550 | 2026-01-27 | Nov 2034 | ≤ 3,024 d | 2026-07-21 |
| AZN | AstraZeneca | — | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX OverexpressionNCT07155226Module 1: Number of participants with dose-limiting toxicity (DLT) | Phase 1/2 | Recruiting | Drug: AZD3632, Posaconazole | Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes | 84 | 2026-01-09 | 2029-02-15 | in 910 d | 2026-07-20 |
| ONC | BeOne Medicines | $545.6B | A Study of BGB-11417 in Participants With Myeloid MalignanciesNCT04771130Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: BGB-11417, Azacitidine, Posaconazole, BGB-11417, BGB-11417 | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm | 260 | 2021-05-24 | 2028-02-08 | in 537 d | 2026-07-13 |
| SNDX | Syndax Pharmaceuticals | $1.8B | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasNCT06226571Dose Escalation: Number of Participants with Dose-limiting Toxicities | Phase 1 | Active, not recruiting | Drug: SNDX-5613, Chemotherapy Regimen, HiDAC | Acute Myeloid Leukemias | 76 | 2024-05-21 | Feb 2027 | ≤ 192 d | 2026-06-30 |
| 4568.T | Daiichi Sankyo | $31.7B | Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionNCT06824168Serious Treatment Emergent Adverse Events (TEAEs) | Phase 2 | Recruiting | Drug: Quizartinib High Dose, Quizartinib Low Dose | Acute Myeloid Leukemia, Leukemia | 130 | 2025-07-18 | 2028-06-06 | in 656 d | 2026-06-22 |
| ABBV | AbbVie | $457.5B | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction TherapyNCT02993523results2023-01-27Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Azacitidine, Venetoclax, Placebo | Acute Myeloid Leukemia (AML) | 443 | 2017-02-02 | 2021-12-01actual | — | 2026-06-11 |
| SNY | Sanofi | — | A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid LeukemiaNCT05712278Incidence of dose-limiting (DLT) toxicity | Phase 1 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: SAR445419, fludarabine, cytarabine | Acute Myeloid Leukaemia | 7 | 2023-06-16 | 2024-02-23actual | — | 2026-06-05 |
| ABBV | AbbVie | $457.5B | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)NCT04161885results2026-06-04Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1) | Phase 3 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Venetoclax, Azacitidine · Other: Best Supportive Care (BSC) | Acute Myeloid Leukemia (AML), Cancer | 465 | 2020-02-26 | 2025-09-23actual | — | 2026-06-04 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive ChemotherapyNCT07623187(Phase 2b and Phase 3) Percentage of participants with Complete Remission (CR) | Phase 2/3 | Not yet recruiting | Biological: IPN60340 + azacitidine + venetoclax · Drug: Placebo + azacitidine + venetoclax | Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | 450 | 2026-11-01 | 2031-05-31 | in 1,745 d | 2026-06-03 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaNCT07623616CR+CRh rate | Phase 2 | Recruiting | Drug: ziftomenib | Acute Myeloid Leukemia (AML) | 6 | 2026-04-23 | Mar 2027 | ≤ 223 d | 2026-06-03 |
| ABBV | AbbVie | $457.5B | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialNCT03844048Number of Participants With Adverse Events | Phase 3 | Active, not recruiting | Drug: Venetoclax | Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer | 165 | 2019-09-06 | Aug 2027 | ≤ 376 d | 2026-05-13 |
| KURA | Kura Oncology, Inc. | $1.1B | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaNCT04067336Phase 1a: Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) | Phase 1/2 | Active, not recruiting | Drug: Ziftomenib, Midazolam, Itraconazole | Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia | 263 | 2019-09-12 | 2028-10-16 | in 788 d | 2026-05-13 |
| BMY | Bristol-Myers Squibb | $134.9B | An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionNCT05413018Relapse-free survival (RFS) | Phase 2 | Active, not recruiting | Drug: CC-486 · Other: Placebo | Leukemia, Myeloid, Acute | 34 | 2022-08-19 | 2025-10-31actual | — | 2026-04-28 |
| SLS | Sellas Life Sciences Group | $2.6B | Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDSNCT05593185expanded access | — | Available | Biological: Galinpepimut-S | Acute Myeloid Leukemia, Myelodysplastic Syndromes | — | — | — | — | 2026-04-24 |
| KURA | Kura Oncology, Inc. | $1.1B | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT06001788Rate of dose limiting toxicities (DLTs) per dose level | Phase 1 | Recruiting | Drug: Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib · Biological: Granulocyte colony-stimulating factor | AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type | 171 | 2024-02-22 | Aug 2026 | ≤ 11 d | 2026-04-14 |
| ABBV | AbbVie | $457.5B | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional ChemotherapyNCT04102020results2025-08-20Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1) | Phase 3 | Completed | Drug: Venetoclax, Azacitidine, Azacitidine | Acute Myeloid Leukemia (AML) | 112 | 2020-03-26 | 2022-09-29actual | — | 2026-04-08 |
| BMY | Bristol-Myers Squibb | $134.9B | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT06419634Incidence of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: BMS-986497, Azacitidine, Venetoclax | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 105 | 2024-05-29 | 2027-02-01 | in 165 d | 2026-04-08 |
| CRSP | CRISPR Therapeutics | $5.1B | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesNCT06492304Phase 1 Part A (dose escalation) and Part B (dose optimization in selected disease types): | Phase 1/2 | Completed | Biological: CTX131 | T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia | 12 | 2024-08-13 | 2026-03-11actual | — | 2026-04-03 |
| 4568.T | Daiichi Sankyo | $31.7B | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodNCT03793478Number of dose-limiting toxicities (Phase 1) | Phase 1/2 | Active, not recruiting | Drug: Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Acute Myeloid Leukemia | 65 | 2018-08-15 | 2027-05-01 | in 254 d | 2026-04-01 |
| INMB | Inmune Bio, Inc. | $59M | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AMLNCT05933070Primary Objective 1 | Phase 1 | Terminatedsponsor's stated reason: Slow/low Enrollment | Biological: INKmune | Cancer, MDS-EB, Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML | 2 | 2020-06-15 | 2024-03-28actual | — | 2026-03-30 |
| CERO | CERo Therapeutics Holdings, Inc. | $852,409 | CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)NCT06834282Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Part 1) | Phase 1 | Recruiting | Drug: CER-1236, Cyclophosphamide, Fludarabine, Mesna | AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 18 | 2025-04-07 | 2026-12-31 | in 133 d | 2026-03-27 |
| CRIS | Curis, Inc. | $22M | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)NCT04278768Determine Maximum Tolerated Dose (MTD) of emavusertib (CA-4948) monotherapy (Phase 1) | Phase 1/2 | Suspendedsponsor's stated reason: Dosing completed in all cohorts. Planning underway for potential additional patient cohorts. | Drug: Emavusertib, Venetoclax, Emavusertib | Acute Myelogenous Leukemia, Myelodysplastic Syndrome | 366 | 2020-07-06 | 2026-04-01 | — | 2026-03-19 |
| SNDX | Syndax Pharmaceuticals | $1.8B | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationNCT04065399Number of participants with dose-limiting toxicities (DLTs) (Phase 1) | Phase 1/2 | Recruiting | Drug: revumenib, cobicistat | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | 447 | 2019-11-05 | 2027-12-15 | in 482 d | 2026-03-18 |
| CDNA | CareDx | $2.4B | Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme TestNCT04635384observationalTo determine the association between increased mixed chimerism (iMC) detected by AlloHeme and post-transplant relapse in patients with acute leukemia and myelodysplastic syndrome. | — | Active, not recruiting | — | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome | 307 | 2021-06-30 | 2026-05-31 | — | 2026-03-18 |
| STTK | Shattuck Labs, Inc. | $748M | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AMLNCT05275439results2026-03-18Safety Profile of SL-172154 Monotherapy or in Combination With Azacitidine | Phase 1 | Terminatedsponsor's stated reason: Development discontinued | Drug: SL-172154, Azacitidine (AZA), Venetoclax | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 106 | 2022-03-17 | 2025-02-06actual | — | 2026-03-18 |
| KURA | Kura Oncology, Inc. | $1.1B | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLNCT05735184Rate of dose limiting toxicities (DLTs) per dose level (Part 1a only) | Phase 1 | Recruiting | Drug: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib | Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia | 420 | 2023-07-18 | Apr 2030 | ≤ 1,349 d | 2026-03-13 |
| CRBU | Caribou Biosciences, Inc. | $167M | Long-Term Follow-up StudyNCT05332054observationalIncidence of targeted NSAEs | — | Enrolling by invitation | Biological: Caribou-sponsored investigational therapy | Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia | 150 | 2022-03-16 | Dec 2041 | ≤ 5,612 d | 2026-03-12 |
| BMY | Bristol-Myers Squibb | $134.9B | Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid LeukemiaNCT07458542observationalRelapse-free survival (RFS) | — | Active, not recruiting | Drug: Azacitidine | Acute Myeloid Leukemia (AML) | 44 | 2025-12-09 | 2026-01-09actual | — | 2026-03-09 |
| BMEA | Biomea Fusion Inc. | $98M | A Phase 1 Study of BMF-500 in Adults With Acute LeukemiaNCT05918692Evaluate the safety and tolerability of BMF-500 by incidence of Treatment Emergent Adverse Events (TEAEs). | Phase 1 | Active, not recruiting | Drug: BMF-500 | Acute Myeloid Leukemia | 35 | 2023-07-26 | Apr 2026 | — | 2026-02-23 |
| ABBV | AbbVie | $457.5B | Expanded Access to ABBV-787NCT06439966expanded access | — | No longer available | Drug: ABBV-787 | Acute Myeloid Leukemia | — | — | — | — | 2026-02-12 |
| BMY | Bristol-Myers Squibb | $134.9B | Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in FranceNCT06565975observationalParticipant real-world relapse-free survival (rw-RFS) | — | Completed | Drug: Oral azacitidine | Acute Myeloid Leukemia (AML) | 112 | 2023-05-23 | 2026-01-26actual | — | 2026-02-12 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionNCT05197426results2026-02-11Recurrence Free Survival (RFS) | Phase 2 | Active, not recruiting | Drug: Oral Azacitidine · Other: Placebo | Acute Myeloid Leukemia | 19 | 2022-01-17 | 2025-01-27actual | — | 2026-02-11 |
| ABBV | AbbVie | $457.5B | Expanded Access to VenetoclaxNCT03123029expanded access | — | Available | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Amyloidosis, Plasma Cell Leukemia | — | — | — | — | 2026-01-30 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsNCT05787496results2026-01-28To Evaluate the Frequency, Duration, and Severity of Treatment-emergent Adverse Events [Safety and Tolerability]. | Phase 1 | Terminatedsponsor's stated reason: As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued. | Drug: NC525 | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome | 28 | 2023-02-28 | 2025-01-31actual | — | 2026-01-28 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesNCT05665530Dose limiting toxicity (DLT) of PRT2527 | Phase 1 | Completed | Drug: PRT2527, Zanubrutinib, Venetoclax | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome | 86 | 2023-09-12 | 2025-06-12actual | — | 2026-01-26 |
| ABBV | AbbVie | $457.5B | A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)NCT03987958observationalOverall Survival | — | Active, not recruiting | — | Acute Myeloid Leukemia | 100 | 2019-08-08 | Jul 2027 | ≤ 345 d | 2026-01-16 |
| CGEM | Cullinan Therapeutics Inc. | $1.3B | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)NCT05143996Number of treatment emergent events (TEAEs) | Phase 1 | Recruiting | Drug: CLN-049 | Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | 60 | 2021-11-18 | Jan 2027 | ≤ 164 d | 2026-01-16 |
| MRKR | Marker Therapeutics, Inc. | $19M | Safety of MT-401-OTS in Patients With Relapsed AML or MDSNCT06552416Safety of MT-401-OTS | Phase 1 | Recruiting | Drug: MT-401-OTS | Acute Myeloid Leukemia, in Relapse, MDS | 40 | 2025-06-16 | Sep 2029 | ≤ 1,137 d | 2025-12-16 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax TabletsNCT05215639observationalPercentage of Participants Achieving Overall Survival (OS) | — | Completed | — | Acute Myeloid Leukemia | 120 | 2021-12-27 | 2025-11-24actual | — | 2025-12-10 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in CanadaNCT05424562observationalOverall Survival (OS) | — | Active, not recruiting | — | Acute Myeloid Leukemia | 210 | 2022-09-07 | Mar 2027 | ≤ 223 d | 2025-11-28 |
| ABBV | AbbVie | $457.5B | Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)NCT04826523observationalPercentage of Participants Who Reported Serious Adverse Event/Drug Reaction | — | Completed | — | Acute Myeloid Leukemia (AML) | 150 | 2021-04-05 | 2025-10-20actual | — | 2025-11-26 |
| AAPG | Ascentage Pharma Group Inc. | — | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaNCT06389292Overall Survival（OS） | Phase 3 | Recruiting | Drug: APG-2575(Lisaftoclax ), Azacitidine Injection · Other: Placebo | Acute Myeloid Leukemia | 486 | 2024-06-11 | 2028-05-25 | in 644 d | 2025-11-25 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | VYxeoS Liposomal Italian Observational Study iN the Real PracticeNCT06143839observationalPercentage of participants showing CR/CRi/CRh without MRD at the end of treatment | — | Completed | Drug: Vyxeos liposomal | Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia | 113 | 2023-12-07 | 2025-10-23actual | — | 2025-11-20 |
| MRKR | Marker Therapeutics, Inc. | $19M | Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantNCT04511130Safety Lead-In | Phase 2 | Terminatedsponsor's stated reason: Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401. | Drug: MT-401 | Acute Myeloid Leukemia, Stem Cell Transplantation | 92 | 2020-10-14 | 2024-03-01actual | — | 2025-10-30 |
| SLS | Sellas Life Sciences Group | $2.6B | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979OS | Phase 3 | Active, not recruiting | Biological: Galinpepimut-S, GM-CSF · Drug: Azacitidine, Venetoclax, Decitabine, Cytarabine · Other: Observation, Montanide | Acute Myeloid Leukemia | 127 | 2021-02-08 | Dec 2025 | — | 2025-10-01 |
| ABBV | AbbVie | $457.5B | A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyNCT03069352results2020-02-28Overall Survival (OS) | Phase 3 | Completed | Drug: Placebo, Venetoclax, Cytarabine | Acute Myeloid Leukemia (AML) | 211 | 2017-05-23 | 2019-02-15actual | — | 2025-09-30 |
| MBRX | Moleculin Biotech, Inc. | $12M | Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)NCT05319587Evaluate the safety and identify the MTD/RP2D of L-Annamycin in combination with a standard regimen of cytarabine (Ara-C, cytosine arabinoside) | Phase 1/2 | Completed | Drug: Liposomal Annamycin, Cytarabine | Leukemia, Myeloid, Acute | 22 | 2022-09-29 | 2023-08-02actual | — | 2025-09-30 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromesNCT05168202results2025-09-25Number of Participants With DLTs | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: CC-95251, Azacitidine, Venetoclax | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | 56 | 2022-01-19 | 2024-07-30actual | — | 2025-09-25 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Long Term Follow-up Study of TScan TCR-T ProductsNCT06976736observationalIncidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | — | Recruiting | Other: Observational | AML, ALL, MDS | 1,000 | 2025-09-09 | Sep 2040 | ≤ 5,155 d | 2025-09-10 |
| ATNM | Actinium Pharmaceuticals | $34M | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514Overall Survival (OS) -Phase 3 | Phase 2/3 | Not yet recruiting | Drug: 131I-apamistamab, Fludarabine, Cyclophosphamide · Radiation: Total Body Irradiation (TBI) · Biological: Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Myelogenous Leukemia, Myelogenous Leukemia, Acute, Myelogenous Leukemia in Relapse, Transplant-Related Disorder, Allogeneic Disease, Refractory AML | 306 | Jan 2026 | Feb 2029 | ≤ 923 d | 2025-09-10 |
| SNY | Sanofi | — | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaNCT03860844results2023-11-15Percentage of Participants With Complete Response (CR) Rate | Phase 2 | Terminatedsponsor's stated reason: Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns. | Drug: Isatuximab, Dexamethasone or equivalent, Fludarabine, Cytarabine, Liposomal daunorubicin, Daunorubicin (nonliposomal), Idarubicin, Filgrastim or equivalent, Mitoxantrone, Doxorubicin, Vincristine, Pegaspargase (PEG) Asparaginase, Cyclophosphamide, Etoposide, Methotrexate, L - Asparginase, Hydroxyurea, L - Asparaginase (Erwinase) | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 67 | 2019-08-06 | 2022-09-12actual | — | 2025-09-09 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.NCT02310321results2024-10-16Phase 1 Part: Maximum Tolerated Dose (MTD) of Gilteritinib | Phase 1/2 | Completed | Drug: Gilteritinib, Idarubicin, Cytarabine | Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia | 97 | 2015-02-26 | 2021-08-25actual | — | 2025-09-02 |
| APTOF | Aptose Biosciences Inc. | — | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT03850574Frequency and severity of drug-related adverse events | Phase 1/2 | Recruiting | Drug: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion | Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia | 240 | 2019-03-11 | Nov 2026 | ≤ 102 d | 2025-08-26 |
| STRO | Sutro Biopharma, Inc. | $365M | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLNCT06679582Evaluate efficacy of luveltamab tazevibulin monotherapy | Phase 1/2 | Terminatedsponsor's stated reason: Terminated Early | Drug: Luveltamab tazevibulin | Acute Myeloid Leukemia (AML) | 24 | 2024-12-04 | 2025-06-01actual | — | 2025-08-24 |
| SNY | Sanofi | — | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological MalignanciesNCT06508489Number of participants with adverse events (AEs)/serious adverse events (SAEs)/adverse events of special interest (AESIs), laboratory abnormalities | Phase 1/2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Biological: SAR443579 · Drug: venetoclax, azacitidine | Acute Myeloid Leukemia | 7 | 2024-08-13 | 2025-08-08actual | — | 2025-08-22 |
| ABBV | AbbVie | $457.5B | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaNCT04086264Safety and Tolerability | Phase 1/2 | Active, not recruiting | Drug: Azacitidine, IMGN632, Venetoclax | Acute Myeloid Leukemia | 218 | 2019-11-06 | Feb 2027 | ≤ 192 d | 2025-08-14 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in ChinaNCT05144243Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 4 | Active, not recruiting | Drug: Venetoclax, Azacitidine | Acute Myeloid Leukemia (AML) | 44 | 2022-01-06 | Mar 2026 | — | 2025-08-12 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaNCT05587049observationalOverall Survival (OS) | — | Recruiting | — | Acute Myeloid Leukemia | 70 | 2023-11-30 | Nov 2026 | ≤ 102 d | 2025-08-08 |
| CLLS | Cellectis S.A. | — | Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT03190278Incidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) [Safety and Tolerability] | Phase 1 | Active, not recruiting | Biological: UCART123v1.2 | Relapsed/Refractory Acute Myeloid Leukemia | 29 | 2017-06-19 | 2024-12-24actual | — | 2025-08-07 |
| VOR | Vor Biopharma | $1.4B | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSNCT04849910Incidence of neutrophil engraftment | Phase 1/2 | Terminatedsponsor's stated reason: Lack of Funding | Biological: VOR33 · Drug: Mylotarg | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | 67 | 2021-12-16 | 2025-05-28actual | — | 2025-07-29 |
| VOR | Vor Biopharma | $1.4B | A Long-term Follow-up Study of Patients Who Received VOR33NCT05309733observationalLong term safety of VOR33 in patients who participated in a VOR33 study in terms of study product-related Adverse Events/Serious Adverse Events (AEs/SAEs). | — | Terminatedsponsor's stated reason: Lack of Funding | Genetic: VOR33 | Leukemia, Myeloid, Acute | 10 | 2022-04-15 | 2025-05-28actual | — | 2025-07-29 |
| VOR | Vor Biopharma | $1.4B | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell TransplantNCT05984199Incidence of dose-limiting toxicities | Phase 1/2 | Terminatedsponsor's stated reason: Lack of Funding | Biological: VCAR33 | Leukemia, Myeloid, Acute | 38 | 2023-12-11 | 2025-05-28actual | — | 2025-07-29 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in GreeceNCT05317494observationalPercentage of Participants Achieving Overall Survival (OS) | — | Recruiting | — | Acute Myeloid Leukemia | 100 | 2022-05-26 | Dec 2026 | ≤ 133 d | 2025-07-16 |
| FHTX | Foghorn Therapeutics Inc. | $401M | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesNCT04891757Incidence of AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), AEs leading to discontinuation, and adverse events of special interest (AESIs); safety laboratory assessments | Phase 1 | Active, not recruiting | Drug: FHD-286, Low Dose Cytarabine, Decitabine | Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | 144 | 2021-06-14 | Sep 2025 | — | 2025-07-10 |
| AMGN | Amgen | $229.9B | AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaNCT02675452results2025-07-09Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) | Phase 1 | Terminatedsponsor's stated reason: sponsor decision, unrelated to safety | Drug: AMG 176, Azacitidine, Itraconazole | Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia | 141 | 2016-06-13 | 2024-05-27actual | — | 2025-07-09 |
| BMEA | Biomea Fusion Inc. | $98M | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLNCT05153330Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4) | Phase 1 | Terminatedsponsor's stated reason: Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure. | Drug: BMF-219 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 55 | 2022-01-24 | 2025-02-13actual | — | 2025-07-03 |
| CRBU | Caribou Biosciences, Inc. | $167M | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT06128044(Part A) Number of patients with dose limiting toxicities (DLT) | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision - Pipeline Reprioritization | Drug: CB-012 | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 12 | 2024-02-08 | 2025-05-30actual | — | 2025-06-11 |
| APVO | Aptevo Therapeutics | $5M | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLNCT06634394To assess the safety, tolerability, and maximum tolerated dose (MTD) of increasing doses of APVO436 in combination with venetoclax/azacitidine in patients with newly diagnosed AML | Phase 1 | Recruiting | Drug: APVO436, Venetoclax, Azacitidine | Acute Myeloid Leukemia (AML) | 39 | 2024-10-01 | Oct 2027 | ≤ 437 d | 2025-05-11 |
| ABBV | AbbVie | $457.5B | Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid LeukemiaNCT04813263observationalPercentage of Participants With ≥ Grade 3 Neutropenia of Venetoclax Regimens With Unfit Acute Myeloid Leukemia (AML) | — | Completed | — | Acute Myeloid Leukemia (AML) | 424 | 2021-05-28 | 2024-04-30actual | — | 2025-04-27 |
| ABBV | AbbVie | $457.5B | A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in ItalyNCT06058741observationalOverall Survival (OS) | — | Active, not recruiting | — | Acute Myeloid Leukemia | 150 | 2024-03-04 | Nov 2026 | ≤ 102 d | 2025-04-22 |
| GILD | Gilead Sciences | $177.9B | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaNCT05079230results2025-04-04Overall Survival (OS) | Phase 3 | Terminatedsponsor's stated reason: Study was terminated due to futility | Drug: Magrolimab, Venetoclax, Azacitidine, Placebo | Acute Myeloid Leukemia | 378 | 2022-07-07 | 2024-04-11actual | — | 2025-04-04 |
| PFE | Pfizer | $155.3B | Latin American Real-world Study in Acute LeukemiaNCT05166135results2025-03-25observationalNumber of Participants According to Health Insurance Type | — | Completed | — | Acute Myeloid Leukemia, Acute Lymphoid Leukemia | 589 | 2021-12-10 | 2022-11-15actual | — | 2025-03-25 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsNCT02649790Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Phase 1/2 | Completed | Drug: KPT-8602, ASTX727, Dexamethasone | Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS | 277 | Jan 2016 | 2024-08-31actual | — | 2025-03-19 |
| BPTH | Bio-Path Holdings, Inc. | $2M | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)NCT05190471Identify Dose Limiting Toxicity (DLT) of BP1002 | Phase 1 | Recruiting | Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP1002) | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 48 | 2022-08-16 | Mar 2027 | ≤ 223 d | 2025-03-10 |
| BPTH | Bio-Path Holdings, Inc. | $2M | Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLNCT02781883Assessment of efficacy in untreated AML subjects by bone marrow aspirate or biopsy | Phase 2 | Recruiting | Drug: BP1001 in combination with Ventoclax plus decitabine, BP1001 plus decitabine | Acute Myeloid Leukemia (AML) | 108 | May 2016 | Dec 2027 | ≤ 498 d | 2025-03-07 |
| APTOF | Aptose Biosciences Inc. | — | A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSNCT04477291Incidence of treatment-emergent adverse events of CG-806 | Phase 1 | Terminatedsponsor's stated reason: Change in corporate strategy | Drug: CG-806 | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 45 | 2020-10-06 | 2024-04-15actual | — | 2025-03-07 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NCT06068868Number of Participants with Adverse Events (AE) | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-787 | Acute Myeloid Leukemia | 36 | 2023-11-13 | 2025-02-25actual | — | 2025-03-06 |
| 4568.T | Daiichi Sankyo Co., Ltd. | $31.7B | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)NCT02834390results2021-08-19Summary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 1 | Completed | Drug: Quizartinib, Cytarabine, Idarubicin, Daunorubicin | Acute Myeloid Leukemia | 7 | 2016-08-12 | 2017-10-19actual | — | 2025-03-05 |
| PFE | Pfizer | $155.3B | A Study Of PF-04449913 In Japanese Patients With Select Hematologic MalignanciesNCT02038777results2022-03-18Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy Cohort | Phase 1 | Completed | Drug: PF-04449913, PF-04449913, Low dose ARA-C (LDAC), PF-04449913, Daunorubicin, Cytarabine, PF-04449913, Azacitidine, PF-04449913, LDAC | Acute Myeloid Leukemia | 48 | 2014-03-25 | 2021-02-12actual | — | 2025-02-26 |
| GILD | Gilead Sciences | $177.9B | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedNCT04778397results2025-02-05Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy | Phase 3 | Terminatedsponsor's stated reason: Study discontinued due to futility. | Drug: Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops | Acute Myeloid Leukemia | 258 | 2021-07-01 | 2024-03-25actual | — | 2025-02-05 |
| NKTX | Nkarta, Inc. | $173M | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSNCT04623944Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Phase 1 | Active, not recruiting | Biological: NKX101 - CAR NK cell therapy | Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes | 61 | 2020-09-21 | 2024-10-02actual | — | 2024-12-27 |
| CELU | Celularity Incorporated | $21M | Natural Killer Cell (CYNK-001) Infusions in Adults with AMLNCT04310592Number of Participants who experience a Dose-limiting Toxicity (DLT) in MRD positive AML patients | Phase 1 | Terminatedsponsor's stated reason: Business reasons | Biological: CYNK-001 | Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML | 27 | 2020-03-12 | 2023-01-20actual | — | 2024-12-12 |
| ALXO | ALX Oncology Inc. | $288M | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)NCT04755244Phase 1: Dose Limiting Toxicities (DLT) | Phase 1 | Terminatedsponsor's stated reason: While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2. | Drug: evorpacept, venetoclax, azacitidine | Acute Myeloid Leukemia, AML, Adult | 14 | 2021-05-05 | 2023-05-05actual | — | 2024-11-27 |
| SLS | Sellas Life Sciences Group | $2.6B | WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)NCT01266083results2024-11-19Overall Survival | Phase 2 | Completed | Biological: Galinpepimut-S, GM-CSF · Other: Montanide | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | 22 | 2011-01-14 | 2016-09-30actual | — | 2024-11-19 |
| SLS | Sellas Life Sciences Group | $2.6B | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersNCT03761914results2024-11-19Overall Response Rate (ORR) - Best Overall Response | Phase 1/2 | Completed | Biological: galinpepimut-S, pembrolizumab, GM-CSF · Other: Montanide | Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer | 26 | 2019-09-30 | 2022-07-05actual | — | 2024-11-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Acute Myeloid Leukemia is matched — 25 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia (AML)
- Leukemia, Myeloid, Acute
- Acute Myelogenous Leukemia
- AML
- Acute Myeloid Leukaemia
- AML, Adult
- Acute Myeloid Leukemia, in Relapse
- Refractory AML
- Relapsed Adult AML
- Relapsed/Refractory Acute Myeloid Leukemia
- Acute Myelogenous Leukemia (AML)
- Relapsed or Refractory Acute Myeloid Leukemia
- Acute Myeloid Leukaemia (AML)
- Refractory Acute Myeloid Leukemia
- AML (Acute Myeloid Leukemia)
- AML With Mutated NPM1
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Acute Myeloid Leukemias
- Leukemia, Acute Myeloid
- Relapsed Acute Myeloid Leukemia
- Relapsed/Refractory AML
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Therapy-Related Acute Myeloid Leukemia
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Acute Myeloid Leukemia” (a text search, wider than this page)